title: [Enhancement of HSP-MUC1 antitumor activity by type C CpG-ODN BW005].
abstract: OBJECTIVE
  To investigate the enhancement of anti-tumor effect of HSP-MUC1 by self-designed type C CpG-ODN BW005.
  
  
  METHODS
  The immunostimulatory effect of CpG-ODN BW005 was detected by IFN protection assay and (3)H proliferation assay in vitro. Sixty C57BL/6 mice were separated into 5 groups randomly, including Sodium Chloride control, HSP-MUC1 control, HSP-MUC1/1585, HSP-MUC1/1826 and HSP-MUC1/BW005. Mice were injected s.c. with agents on day 0, 14 and 28 and were implanted MUC1-EL4 tumor cells s.c. on day 33. Tumor growth and murine death were recorded. Blood was collected in 57 day from tail vein. Subtype of anti-HSP and anti-MUC1 IgG in serum was detected by indirect ELISA.
  
  
  RESULTS
  CpG-ODN BW005 could stimulate the proliferation of hPBMC and mice spleoncyte and IFNalpha production. HSP-MUC1/BW005 postponed tumor development, with the average tumor-developed day of 44.8, and prolonged the survival of mice with the average survival day of 49.5. Moreover, final tumor-developed rate of this group was 33.33%, which was the lowest; final survival rate of this group was 66.67%, which was the highest. Levels of anti-HSP and anti-MUC1 IgG2a in HSP-MUC1/CpG-ODNs group were enhanced.
  
  
  CONCLUSIONS
  CpG-ODN BW005, a kind of type C CpG-ODN, could enhance the anti-tumor effect of HSP-MUC1.
authors.affiliation: Department of Molecular Biology, College of Basic Medicine, Jilin University, Changchun 130021, China.
authors.forename: Xue-Ju
authors.initials: XJ
authors.lastname: Wang
authors.forename: Zhi-Bo
authors.initials: ZB
authors.lastname: Wang
authors.forename: Hong-Fei
authors.initials: HF
authors.lastname: Wei
authors.forename: Xiu-Li
authors.initials: XL
authors.lastname: Wu
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Yong-Li
authors.initials: YL
authors.lastname: Yu
authors.forename: Li-Ying
authors.initials: LY
authors.lastname: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D002461:Cell Line, Transformed; D049109:Cell Proliferation / Q000187:drug effects; D002522:Chlorocebus aethiops; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D006360:Heat-Shock Proteins / Q000235:genetics / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D018396:Mucin-1 / Q000235:genetics* / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D011897:Random Allocation; D015996:Survival Rate; D014162:Transfection; D014709:Vero Cells
chemical_list: D000970:Antineoplastic Agents; C408982:CPG-oligonucleotide; D006360:Heat-Shock Proteins; D007074:Immunoglobulin G; D018396:Mucin-1; D009838:Oligodeoxyribonucleotides